CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform
Jul
10
2024
On demand

CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform

Engineered NK cells are an exciting new therapeutic modality; however, technical challenges have hindered clinical success. Lentiviral vector transduction is a well-established step in producing CAR-T cell therapies, but traditional lentiviral vectors are not well suited to NK cells and yield poor transduction efficiency.

Baboon envelope glycoprotein pseudotyped lentiviral vector (BaEV-LV) has been shown to have robust transduction potential and, in a recent study, it performed better than vesicular-stomatitis-virus-G protein lentiviral vector (VSV-G-LV) in transducing primary NK cells.

Building on those results, this webinar presents new data on BaEV-LV transduction efficiency generated using the CliniMACS Prodigy® NK Cell Engineering platform. The NK cells were isolated first by depletion of CD3+ cells, followed by enrichment of CD56+ cells, then transduced with a BaEV encoding a CAR transgene, and expanded on the Prodigy system in a closed and automated process. These results strongly indicate that BaEV-LV provides superior transduction efficiency, and CAR-NK cell manufacturing with CliniMACS Prodigy generates highly pure CAR-NK cells with potent cytotoxic functionality.

Join the webinar to learn more about:

  • The benefits of BaEV lentiviral vector transduction of NK cells
  • How to implement the CliniMACS NK cell engineering process
  • Utilizing the NK flow cytometry Express Modes on the MACSQuant Analyzer
  • Leveraging Miltenyi Bioindustry expertise in analytical development
Kunal Patel
Kunal Patel
Manager, Process Engineering at Miltenyi Biotec

Kunal Patel is head of Process Engineering for Miltenyi Bioindustry’s CDMO site in San Jose, California. He is responsible for overseeing Process Development activities for the scalable production of cellular therapeutics capable of supporting clinical trials and ultimate commercialization. Kunal has been with Miltenyi Biotec since 2017, and in the cellular therapy CDMO space for over 9 years. During this time, Kunal has contributed to over a dozen programs from pre-clinical development to open INDs.